#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute graft versus host disease Medulloblastoma Breast cancer Univentricular heart Ornithine transcarbamoylase deficiency Neuroendocrine tumour of the lung Gastrointestinal disorder Pancreatic neuroendocrine tumour Chordoma Haemophilia B with anti factor IX Raynaud's phenomenon Marginal zone lymphoma refractory Chronic lymphocytic leukaemia recurrent Anal squamous cell carcinoma Heritable pulmonary arterial hypertension More trials…

    Learn about Rare Diseases

    Indolent systemic mastocytosis – Treatment Factor VIII deficiency – Life with Disease Basal cell naevus syndrome Progressive supranuclear palsy – Trials in Disease Haemophilia B without inhibitors – Treatment MELAS syndrome Carcinoid syndrome – Trials in Disease Hereditary angioedema – Trials in Disease Malignant fibrous histiocytoma – Life with Disease Glycogen storage disease type V – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Carbamazepine Moxifloxacin Xevinapant VORMATRIGINE L-PHENYLALANINE Allopurinol Ucp2 Tianeptine Gemtuzumab Ozogamicin SEPOFARSEN Entrectinib Gsk3915393 Bemcentinib Miransertib For-6219 Bi 3032950 Fipaxalparant Peposertib Retifanlimab 177LU-FAP-2286 More therapies…

    Learn about Your Condition

    Optic ischaemic neuropathy Crohn's disease Obstructive pancreatitis Oesophageal adenocarcinoma Cervical dysplasia Magnetic resonance imaging Metabolic surgery Niemann-Pick disease Dilated cardiomyopathy Takayasu's arteritis Fungal infection Idiopathic pulmonary fibrosis Metastases to lymph nodes Stress urinary incontinence Myofascial pain syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Praglandia s.r.o.

Praglandia s.r.o.

Nadrazni 3368/30a, Smichov, Prague, 150 00, Czechia

Want to learn more about this study or check if you can participate? Contact us.

  • Study on SAR444656 for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    2 1
    Czechia Germany Greece Poland

  • Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

    Not recruiting

    4 1 1 1
    Investigated Drugs:
    • Amlitelimab
    Bulgaria Czechia Denmark France Germany Greece +7

  • Evaluating Once Daily Orforglipron (LY3502970) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight who Have Increased Cardiovascular Risk

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Canagliflozin
    • Dapagliflozin
    • Empagliflozin
    Austria Czechia Germany Greece Italy Romania +2

  • Study on the Effectiveness of Orforglipron for Patients with Obstructive Sleep Apnea and Obesity or Overweight

    Not recruiting

    3 1
    Investigated Diseases:
    • Obesity
    • Overweight
    Investigated Drugs:
    • 3-((1S,2S)-1-(5-((S)-2,2-Dimethyltetrahydro-2H-Pyran-4-Yl)-2-((S)-3-(3-(4-Fluoro-1-Methyl-1H-Indazol-5-Yl)-2-Oxo-2,3-Dihydro-1H-Imidazol-1-Yl)-2-(4-Fluoro-3,5-Dimethylphenyl)-4-Methyl-4,5,6,7-Tetrahydro-2H-Pyrazolo[4,3-C]Pyridine-5-Carbonyl)-1H-Indol-1-Yl)-2-Methylcyclopropyl)-5-Oxo-1,2,4-Oxadiazol-4-Ide Hemicalcium
    Czechia Germany
Previous Page
1 … 4 5 6

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!